Siplizumab

Generic Name: Siplizumab

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 288392-69-8

Unique Ingredient Identifier: KUW1QG1ZM3

Indication: Investigated for use/treatment in psoriasis and psoriatic disorders, transplant (rejection), graft versus host disease, lymphoma (unspecified), and leukemia (unspecified).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Siplizumab in T1DM

Phase 1

Active, not recruiting

Conditions: Type 1 Diabetes Mellitus

Interventions: Drug: Siplizumab

First Posted Date: 2022-10-10

Last Posted Date: 2024-08-02

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 120

Registration Number: NCT05574335

Locations: 🇺🇸
Stanford School of Medicine: Department of Pediatrics, Division of Pediatric Endocrinology and Diabetes, Stanford, California, United States
🇺🇸
Emory University School of Medicine: Emory & Children's Pediatric Research Center, Division of Endocrinology & Diabetes, Atlanta, Georgia, United States
🇺🇸
The University of Chicago: Duchossois Center for Academic Medicine-Hyde Park, Chicago, Illinois, United States

and more 16 locations

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy